We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $1.03, demonstrating a -5.09% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.92% for the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.84%.
Shares of the company have depreciated by 30.77% over the course of the past month, underperforming the Medical sector's gain of 5.26%, and the S&P 500's gain of 1.48%.
Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.02, marking a 80% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $209.65 million, down 0.62% from the year-ago period.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.05 per share and revenue of $877.43 million. These results would represent year-over-year changes of -600% and +6.83%, respectively.
It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Tilray Brands, Inc. boasts a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $1.03, demonstrating a -5.09% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.92% for the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.84%.
Shares of the company have depreciated by 30.77% over the course of the past month, underperforming the Medical sector's gain of 5.26%, and the S&P 500's gain of 1.48%.
Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.02, marking a 80% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $209.65 million, down 0.62% from the year-ago period.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.05 per share and revenue of $877.43 million. These results would represent year-over-year changes of -600% and +6.83%, respectively.
It is also important to note the recent changes to analyst estimates for Tilray Brands, Inc. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Tilray Brands, Inc. boasts a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.